Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Alnylam Pharmaceuticals

ALNYNasdaqWilmington, US-DE, USLarge capWebsite ↗
  • Nasdaq-100
  • Russell 1000

What Alnylam Pharmaceuticals is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to December 31, 2025: $3.71 billion, up 65% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to December 31, 2025: $0.47 billion.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to December 31, 2025: $0.06 billion, up 100% from a year earlier.SEC EDGAR filings (XBRL)
  • Latest earnings call or results release (July 30, 2026): sentiment 0.20 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
  • Guidance in the last 90 days: 1 outlook figure raised, 4 lowered, 2 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 12, 2026): 4 risk factors added, 3 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q2 2026: $2.4 million on the open market.SEC Form 4
  • H-1B filings certified in Q2 2026: 14 (22 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

Company Posture covers S&P 500 companies.

Credit

How these are built →

No bond term sheets or tagged debt on file for Alnylam Pharmaceuticals yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Alnylam Pharmaceuticals: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$0.47BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Alnylam Pharmaceuticals: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Alnylam Pharmaceuticals: revenue, trailing twelve months

$ billions, from SEC filings

$3.7BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Alnylam Pharmaceuticals: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Alnylam Pharmaceuticals: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

3.8Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Alnylam Pharmaceuticals: guidance raised minus lowered

Guidance Ledger statements by quarter

−3.0Data 23 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Alnylam Pharmaceuticals: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.20Data to Jul 2026
ImageDataPalanor calculation
Business

Alnylam Pharmaceuticals: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.70Data to Jul 2026
ImageDataPalanor calculation
Business

Alnylam Pharmaceuticals: risk factors added per annual report

New Item 1A risk factors in each 10-K

4.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Alnylam Pharmaceuticals: H-1B filings certified

Labor Condition Applications by quarter received

14.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Alnylam Pharmaceuticals: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$2.4MData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 20, 2026Lobbying
    Lobbying report (ALNYLAM PHARMACEUTICALS, INC.)third_quarter 2026 · $0.5 million
  2. Oct 20, 2026Lobbying
    Lobbying report (SPLITOAK STRATEGIES LLC)third_quarter 2026 · $0.1 million
  3. Oct 19, 2026Lobbying
    Lobbying report (TIBER CREEK GROUP)third_quarter 2026 · $0.1 million
  4. Oct 19, 2026Lobbying
    Lobbying report (TODD STRATEGY GROUP)third_quarter 2026 · $0.1 million
  5. Oct 19, 2026Lobbying
    Lobbying report (LMH STRATEGIC SOLUTIONS)third_quarter 2026 · $0.1 million
  6. Oct 15, 2026Lobbying
    Lobbying report (CAPITOL COUNSEL LLC)third_quarter 2026 · $0.0 million
  7. Oct 13, 2026Patent
    Patent granted: COMPOSITIONS AND METHODS FOR SILENCING SCN9A EXPRESSIONUS 12760308
  8. Sep 15, 2026Patent
    Patent granted: ENDOSOMAL CLEAVABLE LINKERSUS 12735702
  9. Sep 1, 2026Patent
    Patent granted: METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSIONUS 12723247
  10. Aug 18, 2026Patent
    Patent granted: MANNAN BINDING LECTIN SERINE PEPTIDASE 2 (MASP2) IRNA COMPOSITIONS AND METHODS OF USE THEREOFUS 12709751
  11. Aug 18, 2026Patent
    Patent granted: HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFUS 12709748
  12. Jul 20, 2026Lobbying
    Lobbying report (ALNYLAM PHARMACEUTICALS, INC.)second_quarter 2026 · $0.5 million
  13. Jul 20, 2026Lobbying
    Lobbying report (SPLITOAK STRATEGIES LLC)second_quarter 2026 · $0.1 million
  14. May 27, 20268-K
    Director or officer changeItem 5.02
  15. May 27, 20268-K
    Shareholder vote resultsItem 5.07
  16. Mar 4, 20268-K
    Director or officer changeItem 5.02
  17. Feb 12, 202610-K
    Annual report (10-K)4 risk factors added, 3 removed
  18. Dec 18, 2025Trademark
    Trademark application: SIRELIS
  19. Dec 3, 20258-K
    Director or officer changeItem 5.02
  20. Oct 3, 20258-K
    Material agreement signedItem 1.01
  21. Sep 12, 20258-K
    Material agreement signedItem 1.01
  22. Jun 18, 20258-K
    Director or officer changeItem 5.02
  23. May 13, 20258-K
    Shareholder vote resultsItem 5.07
  24. Mar 5, 20258-K
    Director or officer changeItem 5.02
  25. Feb 13, 202510-K
    Annual report (10-K)2 risk factors added, 1 removed
  26. Dec 19, 2024Risk event
    EPA administrative case: ALNYLAM PHARMECUTICALS INCEPA_ECHO
  27. Feb 15, 202410-K
    Annual report (10-K)4 risk factors added, 4 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Dentsply Sirona XRAY$3.6B$0.1BJun 30, 2026
Bruker BRKR$3.5B$0.1BJun 30, 2026
Veeva Systems VEEV$3.5B—Jul 31, 2026
Charles River Laboratories CRL$4.0B$0.4BJun 27, 2026
BioMarin Pharmaceutical BMRN$3.4B$0.7BJun 30, 2026
Neurocrine Biosciences NBIX$3.4B$0.6BJun 30, 2026
Mettler Toledo MTD$4.1B$0.9BJun 30, 2026
West Pharmaceutical Services WST$3.3B$0.4BJun 30, 2026

Identity

SEC CIK
1178670
LEI
529900S3ZI14OWRJII50
Wikidata
Q16974682

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.